Pfizer withdraws Oxbryta sickle cell treatment from markets due to risk-benefit imbalance.

Pfizer announced it will withdraw its sickle cell disease treatment, Oxbryta, from all approved markets due to clinical data indicating that its risks now outweigh the benefits. The company will also halt all related studies and access programs. Oxbryta, acquired in 2022 for $5.4 billion, was approved in the U.S. in 2019. Pfizer does not expect this decision to affect its financial outlook for 2024.

September 25, 2024
34 Articles